AzTrials
AzTrials

LymphomaPhase 2NCT06826118

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

A Phase 2 study testing Axicabtagene Ciloleucel in people with Lymphoma and Follicular Lymphoma, run by The First Affiliated Hospital of Xiamen University at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lymphoma, Follicular Lymphoma, Refractory Lymphoma
What is being tested?
Axicabtagene Ciloleucel
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
8 Feb 2025to 31 Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2016 classification criteria
  • Subjects with relapsed or refractory FL after prior second-line or higher therapy Prior therapy must include: anti-CD20 monoclonal antibody in combination with an alkylating agent (anti-CD20 monoclonal antibody monotherapy is not eligible as a line of therapy for eligibility). Subjects who have had stable disease (no recurrence) for more than 1 year after completion of their last treatment do not meet the enrollment criteria Translated with DeepL.com (free version)
  • At least one measurable lesion according to the Lugano 2014 classification (Cheson 2014). Lesions with prior radiotherapy were considered measurable only if definitive progression was confirmed after completion of radiotherapy.
  • Patients with FL lymphoma secondary to central may be included in the
  • Previous systemic therapy at least 2 weeks or 5 half-lives (whichever is shorter) from the start of leukapheresis, except for immune checkpoint inhibitors/agonists; Systemic immune checkpoint inhibitor/agonist therapy at least 3 half-lives from leukapheresis (e.g., Ipilimumab, Ivolumab, Pembrolizumab, Atezolizumab, OX40 agonist, 4-IBB agonist). Atezolizumab, OX40 agonist, 4-IBB agonist)
  • Toxic reactions from prior anti-lymphoma therapy must stabilize and recover to ≤ grade 1 (except for non-clinically significant toxicities such as alopecia/balding)
Show all 13Show fewer
  • ≥ 18 years old
  • ECOG physical status score of 0 or 1
  • Absolute neutrophil count (ANC) ≥ 1.0×10^9/L
  • Platelet count ≥ 75×10^9/L
  • Absolute lymphocyte count ≥ 0.1×10^ 9/L
  • Adequate renal, hepatic, pulmonary, and cardiac function, defined as: 1) total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN), except in subjects with Gilbert's syndrome; 2) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN 3) serum creatinine (Cr) ≤ 1.5 x ULN or creatinine clearance (CCr) ≥ 60 mL/min, with creatinine clearance estimated based on the cockcroft-Gault formula; 4) cardiac ejection fraction ≥ 50%, absence of pericardial effusion as determined by echocardiography (ECHO), and absence of clinically significant cardiac arrhythmia; 5) baseline transcutaneous oxygen saturation > 92% under room ventilation; 6) absence of clinically significant chest pain; and ) absence of clinically significant pleural effusion.
  • A negative serum pregnancy test is required for women of childbearing potential (women who have been surgically sterilized or who are at least 2 years postmenopausal are not considered to be of childbearing potential).

Who cannot join

  • Converted FL
  • Small lymphocytic lymphoma
  • The histologic grading of FL was 3b
  • lymphoplasmacytic lymphoma
  • Subject has had other malignant tumors unless he/she has survived disease-free and has not received antitumor therapy for at least 3 years; except for non-melanoma skin tumors, carcinoma in situ (e.g., cervix, bladder, breast)
  • Autologous Hematopoietic Stem Cell Transplantation Within 6 Weeks Prior to Scheduled Infusion of Achille's Bromide Injection
Show all 26Show fewer
  • Has performed allogeneic hematopoietic stem cell transplants
  • Previous CD19-targeted therapy
  • Previous chimeric antigen receptor cell therapy or other genetically modified T-cell therapy.
  • History of severe rapid-onset hypersensitivity reactions to aminoglycosides
  • Presence or suspicion of uncontrolled fungal, bacterial, viral or other infections that require intravenous drug therapy
  • Known human immunodeficiency virus (HIV) infection or active acute or chronic hepatitis infection (HBV or HCV). Subjects with a history of hepatitis must undergo standard serologic or genetic testing in accordance with the most recent version of clinical guidelines/institutional protocols to confirm resolution of infection prior to enrollment.
  • Known history of lymphoma involving the entire gastric wall
  • Presence of any indwelling tube or catheter (e.g., percutaneous nephrostomy tube, indwelling urinary catheter, indwelling biliary drain, or pleural/peritoneal/pericardial catheter). Dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are permitted.
  • Patients with primary central nervous system lymphoma (PCNSL)
  • Subjects with lymphomatous infiltration of the atria or ventricles
  • Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, congestive heart failure class II or worse according to the New York Heart Association cardiac classification, or other clinically significant cardiac disease within 12 months prior to enrollment
  • Anticipated emergencies requiring urgent treatment due to rapid tumor progression within 6 weeks of leukapheresis (e.g., tumor mass compression, tumor lysis syndrome)
  • End-organ damage due to autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) within the past 2 years, or systemic use of immunosuppressive or other systemic disease-control medications. Subjects with a history of autoimmune hypothyroidism who are on a stable dose of thyroid replacement hormone therapy and type I diabetes mellitus on a stable insulin regimen are eligible for enrollment in this study.
  • History of symptomatic deep vein thrombosis (DVT) or pulmonary embolism within 6 months prior to enrollment and history of DVT at the end of the upper extremity within 3 months prior to pretreatment chemotherapy
  • Any medical condition that may affect the assessment of safety or efficacy
  • Has had a severe rapid-onset hypersensitivity reaction to any of the drugs to be used in this study
  • Live, attenuated vaccines administered within ≤6 weeks prior to the start of the pretreatment regimen or whose use is expected to be required during the course of the study;
  • Women of childbearing age who are breastfeeding
  • Male or female subjects who are unwilling to use contraception from the date of signed informed consent until 6 months after completion of pretreatment chemotherapy, or 6 months after completion of an infusion of Aquilensa
  • Male or female subjects who are unwilling to use contraception from the date of signed informed consent until 6 months after completion of pretreatment chemotherapy, or 6 months after completion of an infusion of Aquilensa

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Bing Xu contact

18750918842

xubingzhangjian@126.com

China1 site, 1 recruiting

  • Bing Xu

    Xiamen, Fujian, 361003

    Bing Xu, 18750918842, xubingzhangjian@126.com

    Bing Xu

    Recruiting

Other trials in China

About this study

Official title: A Single-Arm, Multicenter, Prospective, Exploratory Clinical Study of Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment.

Read the detailed description

This study is a single-arm, multicenter, prospective Phase II clinical trial, planning to enroll 30 Chinese subjects with relapsed/refractory follicular lymphoma (R/R FL) who will receive Axicabtagene Ciloleucel Injection. The study aims to assess the efficacy and safety of Axicabtagene Ciloleucel Injection in treating Chinese patients with R/R FL.

Being tested
Axicabtagene Ciloleucel
Medical subject headings
Lymphoma, Lymphoma, Follicular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Axicabtagene CiloleucelDrug

    Also called Axicabtagene Ciloleucel Injection

    Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene Ciloleucel Injection infusion being Day 0).

    Axicabtagene Ciloleucel Injection infusion: A single dose of autologous T cells transduced with chimeric antigen receptor (CAR) in the form of Axicabtagene Ciloleucel Injection will be administered to the subject intravenously. The target dose is 2.0×10^6 anti-CD19 CAR-T cells/kg body weight. The minimum dose that can be used is 1.5×10^6 anti-CD19 CAR-T cells/kg body weight. For subjects with a body weight of ≥100 kg, the maximum total dose is 2.0×10^8 anti-CD19 CAR-T cells

Study groups in NCT06826118
Study groupRoleWhat they receive
Axicabtagene Ciloleucel InjectionExperimentalThe total blood volume circulated is recommended to be approximately 8-10 liters to obtain about (5-10)×10^9 mononuclear cells. The collected sample will be packaged according to the study product manual and quickly transported to the cell preparation center for the preparation of Axicabtagene Ciloleucel Injection. Pre-treatment chemotherapy. Axicabtagene Ciloleucel Injection infusion.
Receives: Drug: Axicabtagene Ciloleucel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Best Objective Response Rate (bORR) at 6 months

    This is defined as the proportion of subjects in the modified Intent-To-Treat (mITT) analysis set who achieve a best response of Complete Remission (CR) or Partial Remission (PR) following infusion of Axicabtagene Ciloleucel Injection, as determined by the treating physician, and who have the opportunity to complete the 6-month assessment. Before the data cutoff date, all subjects who do not meet the criteria for objective response will be considered as having no objective response (e.g., those without valid assessments or who did not undergo efficacy evaluation).

    Measured: Up to 36 months

Secondary outcomes (5)

  1. Progression-Free Survival (PFS)

    Defined as the time interval from the date of Axicabtagene Ciloleucel Injection infusion to the date of disease progression or death due to any cause (whichever occurs first) in the modified Intent-To-Treat (mITT) analysis set.

    Measured: Up to 36 months

  2. Complete Response (CR) Rate

    Defined as the proportion of subjects in the modified Intent-To-Treat (mITT) analysis set who achieve a best response of Complete Response (CR) as determined by the treating physician.

    Measured: Up to 36 months

  3. Partial Response (PR) Rate

    Defined as the proportion of subjects in the modified Intent-To-Treat (mITT) analysis set who achieve a best response of Partial Response (PR) as determined by the treating physician.

    Measured: Up to 36 months

  4. Duration of Response (DOR)

    Defined as the time interval from the first documented complete or partial response to disease progression or death due to any cause (whichever occurs first) among subjects who achieve an objective response in the modified Intent-To-Treat (mITT) analysis set.

    Measured: Up to 36 months

  5. Overall Survival (OS)

    Defined as the time interval from the infusion of Axicabtagene Ciloleucel Injection to death due to any cause in the modified Intent-To-Treat (mITT) analysis set. All subjects, regardless of whether they receive any additional anti-tumor treatment after infusion, will be followed up for survival information. The causes of death will also be reported.

    Measured: Up to 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Feb 2025
  2. Study start8 Feb 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Axicabtagene Ciloleucel Injection
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06826118
Sponsor's protocol ID
XMDYYYXYK-16
Status last verified
Feb 2025
First submitted
10 Feb 2025
Last updated
13 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Axicabtagene Ciloleucel in people with Lymphoma and Follicular Lymphoma, run by The First Affiliated Hospital of Xiamen University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Bing Xu (18750918842, xubingzhangjian@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Best Objective Response Rate (bORR) at 6 months (time frame: Up to 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06826118.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in